Cargando…

Investigating the effectiveness of different aspirin dosing regimens and the timing of aspirin intake in primary and secondary prevention of cardiovascular disease: protocol for a systematic review

BACKGROUND: Once-daily low-dose aspirin is routinely used for the prevention of secondary events in cardiovascular disease (CVD). The routine use of aspirin in primary prevention of CVD is less clear due to a finer balance between benefits and harms. In addition, the variability in benefit achievabl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bem, Danai, Dretzke, Janine, Stevens, Simon, Lordkipanidzé, Marie, Hodgkinson, James, Bayliss, Sue, Moore, David, Fitzmaurice, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4475616/ https://www.ncbi.nlm.nih.gov/pubmed/26088608 http://dx.doi.org/10.1186/s13643-015-0078-3

Ejemplares similares

Protocol for a systematic review of the diagnostic and prognostic utility of tests currently available for the detection of aspirin resistance in patients with established cardiovascular or cerebrovascular disease
por: Raichand, Smriti, et al.
Publicado: (2013)

Methodological issues and recommendations for systematic reviews of prognostic studies: an example from cardiovascular disease
por: Dretzke, Janine, et al.
Publicado: (2014)

Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease
por: Gallagher, Hugh, et al.
Publicado: (2022)

Protocol for a systematic review and economic evaluation of the clinical and cost-effectiveness of non-hospital-based non-invasive ventilation (NIV) in patients with stable end-stage COPD with hypercapnic respiratory failure
por: Dave, Chirag, et al.
Publicado: (2014)

Pre-clinical evaluation of therapies to prevent or treat bone non-union: a systematic review protocol
por: Stewart, Sarah K., et al.
Publicado: (2015)

Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins
por: De Berardis, Giorgia, et al.
Publicado: (2007)

Low dose aspirin and pregnancy: how important is aspirin resistance?
por: Navaratnam, K, et al.
Publicado: (2016)

A description of the methods of the aspirin supplementation for pregnancy indicated risk reduction in nulliparas (ASPIRIN) study
por: Hoffman, Matthew K., et al.
Publicado: (2017)

Low-dose aspirin for primary and secondary prevention of cardiovascular events in Denmark 1998–2018
por: Christensen, Mikkel B., et al.
Publicado: (2021)

Thrombosis and Aspirin: Clinical Aspect, Aspirin in Cardiology, Aspirin in Neurology, and Pharmacology of Aspirin
por: Doutremepuich, Christian
Publicado: (2012)

Cost-Effectiveness of Aspirin Adherence for Secondary Prevention of Cardiovascular Events
por: Djatche, Laurence M., et al.
Publicado: (2018)

Challenging the “Divinity” of Aspirin Monotherapy for Secondary Prevention of Cardiovascular Disease
por: Spartalis, Michael, et al.
Publicado: (2023)

Platelets, Aspirin and Cardiovascular Disease
por: Elwood, P. C.
Publicado: (1976)

Aspirin for Prevention of Cardiovascular Disease
por: Mendy, Vincent L., et al.
Publicado: (2017)

Protocol for a systematic review of prognostic models for the recurrence of venous thromboembolism (VTE) following treatment for a first unprovoked VTE
por: Ensor, Joie, et al.
Publicado: (2013)

The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B(2) assay as an evaluation tool of different aspirin dosing regimens in the clinical setting
por: De Stefano, Valerio, et al.
Publicado: (2018)

Low-dose aspirin and rivaroxaban combination therapy to overcome aspirin non-sensitivity in patients with vascular disease
por: Khan, Hamzah, et al.
Publicado: (2022)

Aspirin for primary prevention of cardiovascular disease
por: Nansseu, Jobert Richie N., et al.
Publicado: (2015)

Aspirin for Primary Prevention of Cardiovascular Disease
por: Kim, Ji Hye, et al.
Publicado: (2019)

Gastrointestinal symptoms in low-dose aspirin users: a comparison between plain and buffered aspirin
por: Jaspers Focks, J., et al.
Publicado: (2014)

The Effect of Low-Dose Aspirin on Frailty in Older Adults in the Aspirin in Reducing Events in the Elderly Study
por: Espinoza, Sara, et al.
Publicado: (2021)

Aspirin in essential thrombocythemia. For whom? What formulation? What regimen?
por: Cattaneo, Marco
Publicado: (2023)

PA32540 for the secondary prevention of cardiovascular disease in patients at risk for aspirin-associated gastric ulcers
por: Duffy, Danielle, et al.
Publicado: (2014)

Effects of Low-Dose Aspirin Therapy on Thermoregulation in Firefighters
por: McEntire, Serina J., et al.
Publicado: (2015)

Efficacy and safety of lumbrokinase plus aspirin versus aspirin alone for acute ischemic stroke (LUCENT): study protocol for a multicenter randomized controlled trial
por: Chen, Ying, et al.
Publicado: (2022)

Body image dissatisfaction in patients with inflammatory bowel disease: a systematic review protocol
por: Beese, Sophie Elizabeth, et al.
Publicado: (2018)

The antithrombotic profile of aspirin. Aspirin resistance, or simply failure?
por: Altman, Raul, et al.
Publicado: (2004)

Mechanism of Improving Aspirin Resistance: Blood-Activating Herbs Combined With Aspirin in Treating Atherosclerotic Cardiovascular Diseases
por: Zhao, Yixi, et al.
Publicado: (2021)

Low-Dose Aspirin for Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease
por: Kim, Ae Jin, et al.
Publicado: (2014)

Biomarkers for predicting response to long‐term high dose aspirin therapy in aspirin‐exacerbated respiratory disease
por: Mastalerz, Lucyna, et al.
Publicado: (2021)

Determination of an optimal dosing regimen for aspirin chemoprevention of 1,2-dimethylhydrazine-induced colon tumours in rats
por: Barnes, C J, et al.
Publicado: (1999)

Aspirin overutilization for the primary prevention of cardiovascular disease
por: VanWormer, Jeffrey J, et al.
Publicado: (2014)

Aspirin for primary prevention of cardiovascular disease in diabetes
por: Xing, Ying, et al.
Publicado: (2019)

Aspirin for the primary prevention of cardiovascular disease in the elderly
por: O’Sullivan, Jack W
Publicado: (2019)

Use and Misuse of Aspirin in Primary Cardiovascular Prevention
por: Coccheri, Sergio
Publicado: (2017)

Aspirin in the Modern Era of Cardiovascular Disease Prevention
por: Murphy, Ella, et al.
Publicado: (2021)

Aspirin in primary prevention of cardiovascular disease in diabetes
por: Papazafiropoulou, Athanasia K., et al.
Publicado: (2021)

Alarming Symptoms after A Dose of Aspirin
por: Bullock, J. E.
Publicado: (1909)

Effects of low-dose aspirin in subjects with dyslipidemia
por: Lou, Guozhong, et al.
Publicado: (2016)

Low-dose Btk inhibitors: an ‘aspirin’ of tomorrow?
por: Payrastre, Bernard, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jssee04de2mb8m5alb1drj7kha